The U.S. Food and Drug Administration on Friday approved drug for treating metastatic breast cancers linked to the BRCA gene mutation. These mutated genes, called BRCA1 and BRCA2, first came to prominence in five years ago. According to FDA, expanding approval of Lynparza (olaparib) to include use against BRCA-linked tumors that have spread beyond the breast. Lynparza is one of a group of powerful new cancer drugs known as PARP inhibitors, and it's the first such drug to be approved for use against breast cancer.
This approval demonstrates the current paradigm of developing drugs that target the underlying genetic causes of a cancer, often across cancer types. BRCA mutations are involved in up to one in every four breast cancers that are thought to have a hereditary component. These aberrant genes are also implicated in between 5 and 10 percent of non-hereditary breast tumors. When it's functioning properly, BRCA actually helps repair damaged cellular DNA and prevent tumors, but when BRCA1 and BRCA2 go awry they instead encourage breast cancers.
PARP inhibitor medicines such as Lynparza appear to interfere with the function of mutated BRCA with breast cells, causing them to die rather replicate-slowing tumor growth. The safety and effectiveness of Lynparza for women with advanced BRCA-linked breast cancers was established after a trial on patients. The trial measured the length of time the tumors did not have significant growth after treatment. The median progression-free survival for patients taking Lynparza was 7 months compared to 4.2months for patients taking chemotherapy only.
Common side effects of Lynparza include anemia, low white blood cell counts, nausea, fatigue, vomiting, headache, joint pain, increased susceptibility to colds and other respiratory tract infections, and other effects. Because Lynparza can harm a developing fetus, women are advised to use contraception while on the drug. Women should also not breast-feed while using Lynparza.
haleplushearty.blogspot.com
